Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06906341 · ClinicalTrials.gov registry record · Phase 2
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
A Phase 2 study of Ovarian Cancer and Endometrial Cancer, sponsored by Corcept Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 270
- Enrollment target
- 20
- Study locations
NCT06906341 is a Phase 2 study of Ovarian Cancer and Endometrial Cancer that is actively recruiting participants, run by Corcept Therapeutics. The registered enrollment target is 270 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT06906341, a Phase 2 study of Ovarian Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Corcept Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 270 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
Conditions Studied
Interventions
- DRUG Relacorilant 150 mg once daily (QD)
- DRUG Nab-paclitaxel 80 mg/m^2
- DRUG Bevacizumab 10 mg/kg
Study Locations (20)
Other
- 328 - Aalst
- 326 - Charleroi
- 325 - Hasselt
- 108 - Leuven
- 306 - Lille
- 307 - Nancy
California
- 150 - Palo Alto
- 014 - San Francisco
Florida
- 544 - Fort Myers
- 543 - West Palm Beach
Missouri
- 334 - Kansas City
- 521 - St Louis
Virginia
- 522 - Fairfax
- 300 - Norfolk
Minnesota
- 518 - Minneapolis
New Mexico
- 292 - Albuquerque
Ohio
- 304 - Centerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2025-04-11 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06906341
The ClinicalTrials.gov registry entry for NCT06906341 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (63% lower). The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which Relacorilant 150 mg once daily (QD) is the first listed.
NCT06906341 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06906341 about?
NCT06906341 is a clinical study titled "Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers". This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
What is the current status of trial NCT06906341?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2025-04-11. Estimated completion is 2026-12.
What conditions does trial NCT06906341 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms.
What interventions are being tested in trial NCT06906341?
The interventions under investigation include: Relacorilant 150 mg once daily (QD) (DRUG), Nab-paclitaxel 80 mg/m^2 (DRUG), Bevacizumab 10 mg/kg (DRUG).
Who is sponsoring clinical trial NCT06906341?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06906341 being conducted?
This trial has 20 study locations across California, Florida, Minnesota, Missouri, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.